changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use.
For Medical questions regarding any BTG products, please contact email@example.com
Treat PE with EKOS™
The EKOS® Control Unit 4.0 is designed to support a new standard of PE treatment – allowing physicians to use one control unit to treat both pulmonary arteries
The EKOS Control Unit 4.0 is not available for sale in all countries
Read the SEATTLE II and OPTALYSE PE study results in our Learning Center
Find your PE Resources here
OPTALYSE PE Trial: Acute and 1-year results
Patient Story - Chronic DVT
Learn more about our ongoing collaborations in research trials.
Review successful EKOS™ case studies for treatment of PE, DVT and PAO.
Did you know EKOS™ System is the first device cleared by the FDA for the treatment of
ULTIMA Trial Summary
SEATTLE II Trial Summary
OPTALYSE PE Trial Summary
Arizona Patients Successfully Receive th...
Recommended Cash Offer for BTG plc by Bo...
BTG plc: Interim Results 2018
OPTALYSE PE Results Presented at Society...
Healthcare Player BTG on lookout for acq...
NICE highlights potential role of TheraS...